Why Packaging Format Matters in Stability Studies

The physical and chemical properties of the packaging material directly influence the degradation kinetics of the product. Packaging acts as a barrier against:

• ✓ Moisture (hydrolysis-sensitive APIs)
• ✓ Oxygen (oxidation-prone drugs)
• ✓ Light (photolabile formulations)
• ✓ Volatile impurities or odors

According to ICH Q1A(R2), the packaging used in stability studies must be the same as proposed for commercial distribution, including secondary packaging where it affects stability.

Aluminum Foil Packaging: Strengths and Risks

Aluminum foil is known for its excellent barrier properties against light, moisture, and gases. However, challenges include:

• Delamination: Breakdown of laminate layers in hot/humid conditions
• Chemical reactivity: Especially with acidic or basic drugs when foil is in direct contact
• Pinhole defects: Can allow moisture ingress, leading to false-negative results

To mitigate these risks, foil should be combined with inert layers like polyethylene or PVC and validated under accelerated conditions.

Blister Packs: Alu-Alu vs. Alu-PVC

Blister packaging is common for solid oral dosage forms. Two primary types are:

• Alu-Alu: High barrier to light, moisture, and gases. Suitable for moisture-sensitive APIs.
• Alu-PVC: Lower barrier properties but cost-effective. Risk of moisture ingress over time.

Stability testing must reflect the final packaging type, including individual cavity sealing performance and blister thickness variations.

Flexible Pouch Packaging: Stability Challenges

Pouches are often used for powders, liquids, or multi-dose formats. Risks associated with this format include:

• Seal integrity issues: Heat seal parameters affect air/moisture permeability
• WVTR and OTR concerns: Flexible laminates may allow gradual ingress over time
• Migration of ink or adhesives: Especially when stored under accelerated conditions

Ensure pouch materials pass USP and for water vapor and oxygen transmission rates before use in stability testing.

Case Study: Drug Degradation in Alu-PVC Blister vs. Alu-Alu

A pharmaceutical company evaluated the stability of a moisture-sensitive tablet using two blister formats. After 6 months at 40°C/75% RH, the assay dropped by 8% in Alu-PVC due to moisture ingress, while Alu-Alu retained 99% potency. Based on this result, the sponsor changed to Alu-Alu for all climatic zones.

Checklist for Packaging Stability Evaluation

• ☑ Validate packaging with actual drug product
• ☑ Include foil thickness, blister material type, and pouch lamination layers in protocol
• ☑ Conduct WVTR and OTR testing on packaging samples
• ☑ Evaluate packaging performance at 25°C/60% RH, 30°C/65% RH, and 40°C/75% RH
• ☑ Conduct integrity testing after drop, vibration, and stress simulations

Analytical Testing Considerations

• Moisture content (KF titration for tablets or films)
• Assay and related substances by validated HPLC method
• Photostability per ICH Q1B if blister is transparent
• Visual inspection for blister delamination or seal rupture
• Oxygen content inside pouches using headspace gas analyzers

Documentation for Regulatory Submissions

• Summary of packaging specifications
• Justification for packaging choice based on stability data
• Compatibility study results including leachables/extractables
• Signed reports of WVTR and seal strength tests
• Packaging description in CTD Module 3.2.P.7

Regulatory Insights and Expectations

Agencies such as CDSCO and EMA emphasize packaging consistency between stability batches and commercial lots. It is unacceptable to conduct stability with Alu-Alu blister and market with Alu-PVC unless bridging data is provided.

As per clinical trial protocol requirements, packaging must also be validated during investigational studies to ensure patient safety and data reliability.

Conclusion

Foil wraps, blister packs, and pouches are critical packaging formats, but they come with stability testing complexities. Moisture ingress, seal integrity, and material interaction with the API are common concerns. Through robust packaging evaluation, material qualification, and regulatory alignment, these challenges can be addressed to ensure product quality and shelf life.

References:

• ICH Q1A(R2) Stability Testing Guidelines
• ICH Q1B Photostability Testing
• USP Chapters , , ,
• WHO TRS 1010 Annex 10 – Stability Studies
• FDA Guidance on Container Closure Systems

Why packaging material compatibility matters in stability testing:

Pharmaceutical packaging isn’t just about external protection—it directly impacts the stability, safety, and shelf life of the product. Materials like gaskets, liners, induction seals, and stoppers interact with the product or its environment, especially under ICH-simulated conditions. If these materials degrade, migrate, or fail over time, they can compromise product quality and patient safety.

Ensuring packaging component compatibility is essential before locking stability protocols or selecting commercial packaging formats.

How degradation or incompatibility can occur:

Elevated temperatures and humidity in accelerated or long-term studies can cause seal materials to shrink, leach additives, or lose elasticity. For instance, polyethylene liners may become brittle, or rubber gaskets may deform under high RH, breaking the seal. These changes can lead to moisture ingress, impurity formation, or compromised sterility.

Case examples of real-world compatibility failures:

In past cases, blister foils failed under Zone IVb conditions due to adhesive migration, or tube liners softened under humid storage, altering viscosity and content uniformity. Such failures were often caught late, triggering revalidation and delayed submissions.

Regulatory and Technical Context:

ICH Q1A(R2) and container-closure evaluation:

ICH Q1A(R2) mandates that stability studies include the final packaging system and that the container-closure system must protect product quality throughout its shelf life. ICH Q3C and Q3D also relate to extractables and leachables risks associated with poor packaging compatibility.

Module 3.2.P.7 of the CTD requires complete justification for packaging selection, including physical, chemical, and biological compatibility with the product and the stability environment.

Audit expectations and packaging traceability:

During audits, regulators may request vendor specifications, extractables/leachables data, and documented compatibility studies. If multiple stability studies use the same packaging across formulations, a single compatibility assessment is not enough—each drug-product combination requires its own validation.

Best Practices and Implementation:

Perform stress testing on critical packaging components:

Expose gaskets, liners, seals, and stoppers to stability storage conditions (e.g., 40°C/75% RH) for defined durations. Evaluate changes in physical integrity (e.g., compression set, dimensional stability), visual appearance (e.g., discoloration), and chemical behavior (e.g., leachable profiles).

Use headspace analysis, FTIR, or GC-MS to identify potential volatile degradation byproducts or leachates from packaging components.

Align compatibility testing with product risk profile:

High-risk products—such as biologics, inhalers, or parenterals—require deeper compatibility evaluation, including toxicity risk assessments and interaction studies. Include liner-gasket compatibility for screw caps, heat-seal failure risk for sachets, and stopper-core alignment for injectable vials.

Involve packaging development and QA teams in material specification review, change control, and stability chamber qualification processes.

Document and link compatibility findings to SOPs and protocols:

Include compatibility results in packaging qualification reports and cross-reference them in stability protocols. Define packaging acceptance criteria, materials of construction, and vendor control mechanisms within SOPs.

Ensure that any packaging changes trigger reassessment of compatibility under real and accelerated stability conditions, and maintain traceable logs of version control for all packaging used in studies.